{"entity":{"id":"nct07213609","kind":"trial","name":"A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of GSK5460025 in colorectal cancer, run by GlaxoSmithKline, now recruiting.","summary":"A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors is a phase 1/2 interventional study registered as NCT07213609 by GlaxoSmithKline, with 47 participants planned, started 2025-10-20 and due to reach its primary completion in 2028-09-28. Interventions recorded: GSK5460025.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07213609","url":"https://clinicaltrials.gov/study/NCT07213609"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["gsk"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07213609","phase":"1/2","setting":"A Phase 1/2 Open-label, Multicenter Study of Oral GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Adult Participants With Mismatch Repair-deficient (dMMR) or Microsatellite Instability-High (MSI-H) Solid Tumors","sponsor":"GlaxoSmithKline","enrolled":47,"outcomes":[]},"route":"/trials/nct07213609/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}],"company":[{"id":"gsk","kind":"company","name":"GSK","route":"/companies/gsk/"}]}}